Anixa Biosciences Inc (ANIX) SEC Filing 10-Q Quarterly Report for the period ending Saturday, April 30, 2022

Anixa Biosciences Inc

CIK: 715446 Ticker: ANIX
Cover - shares
6 Months Ended
Apr. 30, 2022
Jun. 10, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateApr. 30, 2022 
Document Fiscal Period FocusQ2 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--10-31 
Entity File Number001-37492 
Entity Registrant NameANIXABIOSCIENCES, INC. 
Entity Central Index Key0000715446 
Entity Tax Identification Number11-2622630 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One3150 Almaden Expressway 
Entity Address, Address Line TwoSuite 250 
Entity Address, City or TownSan Jose 
Entity Address, State or ProvinceCA 
Entity Address, Postal Zip Code95118 
City Area Code(408) 
Local Phone Number708-9808 
Title of 12(b) SecurityCommon Stock, par value $.01 per share 
Trading SymbolANIX 
Security Exchange NameNASDAQ 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 30,471,001

View differences made from one quarter to another to evaluate Anixa Biosciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anixa Biosciences Inc.


Assess how Anixa Biosciences Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
Filter Subcategory:
Cash Flow
Inside Anixa Biosciences Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits

Ticker: ANIX
CIK: 715446
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-016452
Submitted to the SEC: Fri Jun 10 2022 4:22:36 PM EST
Accepted by the SEC: Fri Jun 10 2022
Period: Saturday, April 30, 2022
Industry: Medical Laboratories

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: